Serum LL-37 levels associated with severity of bronchiolitis and viral etiology

Clinical Infectious Diseases

Volumn 65, Issue 6, 2017, Pages 967-975

  Mansbach, Jonathan M ^a   Hasegawa, Kohei ^b   Ajami, Nadim J ^c   Petrosino, Joseph F ^c   Piedra, Pedro A ^d   Tierney, Courtney N ^b   Espinola, Janice A ^b   Camargo, Carlos A ^b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c Alkek Center for Metagenomics and Microbiome Research Center   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Bronchiolitis; Ll 37; Microbiota; Respiratory syncytial virus; Severity of illness

Indexed keywords

CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; ANTIMICROBIAL CATIONIC PEPTIDE; CAP18 LIPOPOLYSACCHARIDE-BINDING PROTEIN;

ARTICLE; CHILD HOSPITALIZATION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HAEMOPHILUS; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; INFANT; INTENSIVE CARE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORAXELLA; NASOPHARYNGEAL ASPIRATION; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; REAL TIME POLYMERASE CHAIN REACTION; RHINOVIRUS; STREPTOCOCCUS; VIRAL BRONCHIOLITIS; VIRUS ETIOLOGY; VIRUS PATHOGENESIS; WINTER; BLOOD; BRONCHIOLITIS; CLINICAL TRIAL; COMMON COLD; COMPLICATION; ISOLATION AND PURIFICATION; MULTICENTER STUDY; NASOPHARYNX; PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SEVERITY OF ILLNESS INDEX; VIROLOGY;

ANTIMICROBIAL CATIONIC PEPTIDES; BRONCHIOLITIS; BRONCHIOLITIS, VIRAL; COINFECTION; COMMON COLD; CRITICAL CARE; FEMALE; HUMANS; INFANT; LENGTH OF STAY; MALE; NASOPHARYNX; PROSPECTIVE STUDIES; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; RHINOVIRUS; SEVERITY OF ILLNESS INDEX;

EID: 85031943419     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cix483     Document Type: Article

References (39)

1. Yorita KL, Holman RC, Sejvar JJ, Steiner CA, Schonberger LB. Infectious disease hospitalizations among infants in the United States. Pediatrics 2008; 121:244-52.
2. Hasegawa K, Tsugawa Y, Brown DF, Mansbach JM, Camargo CA Jr. Trends in bronchiolitis hospitalizations in the United States, 2000-2009. Pediatrics 2013; 132:28-36.
3. Mansbach JM, Piedra PA, Teach SJ, et al; MARC-30 Investigators. Prospective multicenter study of viral etiology and hospital length of stay in children with severe bronchiolitis. Arch Pediatr Adolesc Med 2012; 166:700-6.
4. Mansbach JM, McAdam AJ, Clark S, et al. Prospective multicenter study of the viral etiology of bronchiolitis in the emergency department. Acad Emerg Med 2008; 15:111-8.
5. Durr UH, Sudheendra US, Ramamoorthy A. LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochim Biophys Acta 2006; 1758:1408-25.
6. Hilchie AL, Wuerth K, Hancock RE. Immune modulation by multifaceted cationic host defense (antimicrobial) peptides. Nat Chem Biol 2013; 9:761-8.
7. Gombart AF, Bhan I, Borregaard N, et al. Low plasma level of cathelicidin antimicrobial peptide (hCAP18) predicts increased infectious disease mortality in patients undergoing hemodialysis. Clin Infect Dis 2009; 48:418-24.
8. Currie SM, Findlay EG, McHugh BJ, et al. The human cathelicidin LL-37 has antiviral activity against respiratory syncytial virus. PLoS One 2013; 8:e73659.
9. Currie SM, Gwyer Findlay E, McFarlane AJ, et al. Cathelicidins have direct antiviral activity against respiratory syncytial virus in vitro and protective function in vivo in mice and humans. J Immunol 2016; 196:2699-710.
10. Harcourt JL, McDonald M, Svoboda P, Pohl J, Tatti K, Haynes LM. Human cathelicidin, LL-37, inhibits respiratory syncytial virus infection in polarized airway epithelial cells. BMC Res Notes 2016; 9:11.
11. Schogler A, Muster RJ, Kieninger E, et al. Vitamin D represses rhinovirus replication in cystic fibrosis cells by inducing LL-37. Eur Respir J 2016; 47:520-30.
12. Mansbach JM, Piedra PA, Borregaard N, et al. Serum cathelicidin level is associated with viral etiology and severity of bronchiolitis. J Allergy Clin Immunol 2012; 130:1007-8.e1.
13. Hasegawa K, Mansbach JM, Ajami NJ, et al. Serum cathelicidin, nasopharyngeal microbiota, and disease severity among infants hospitalized with bronchiolitis. J Allergy Clin Immunol 2017; 139:1383-6.
14. Han JE, Jones JL, Tangpricha V, et al. High dose vitamin D administration in ventilated intensive care unit patients: A pilot double blind randomized controlled trial. J Clin Transl Endocrinol 2016; 4:59-65.
15. Hasegawa K, Jartti T, Mansbach JM, et al. Respiratory syncytial virus genomic load and disease severity among children hospitalized with bronchiolitis: multicenter cohort studies in the United States and Finland. J Infect Dis 2015; 211:1550-9.
16. Leaf DE, Waikar SS, Wolf M, Cremers S, Bhan I, Stern L. Dysregulated mineral metabolism in patients with acute kidney injury and risk of adverse outcomes. Clin Endocrinol (Oxf) 2013; 79:491-8.
17. Powe CE, Ricciardi C, Berg AH, et al. Vitamin D-binding protein modifies the vitamin D-bone mineral density relationship. J Bone Miner Res 2011; 26:1609-16.
18. Beckham JD, Cadena A, Lin J, et al. Respiratory viral infections in patients with chronic, obstructive pulmonary disease. J Infect 2005; 50:322-30.
19. Knorr L, Fox JD, Tilley PA, Ahmed-Bentley J. Evaluation of real-Time PCR for diagnosis of Bordetella pertussis infection. BMC Infect Dis 2006; 6:62.
20. Winchell JM, Thurman KA, Mitchell SL, Thacker WL, Fields BS. Evaluation of three real-Time PCR assays for detection of Mycoplasma pneumoniae in an outbreak investigation. J Clin Microbiol 2008; 46:3116-8.
21. Hasegawa K, Mansbach JM, Ajami NJ, et al. Association of nasopharyngeal microbiota profiles with bronchiolitis severity in infants hospitalized for bronchiolitis. Eur Respir J 2016; 48:1329-39.
22. Wu GD, Chen J, Hoffmann C, et al. Linking long-Term dietary patterns with gut microbial enterotypes. Science 2011; 334:105-8.
23. Rousseeuw PJ. Silhouettes: A graphical aid to the interpretation and validation of cluster analysis. J Comput Appl Math 1987; 20:53-65.
24. Jartti T, Hasegawa K, Mansbach JM, Piedra PA, Camargo CA Jr. Rhinovirusinduced bronchiolitis: lack of association between virus genomic load and shortterm outcomes. J Allergy Clin Immunol 2015; 136:509-12.e11.
25. Mansbach JM, Piedra PA, Stevenson MD, et al; MARC-30 Investigators. Prospective multicenter study of children with bronchiolitis requiring mechanical ventilation. Pediatrics 2012; 130:e492-e500.
26. Hasegawa K, Mansbach JM, Camargo CA Jr. Infectious pathogens and bronchiolitis outcomes. Expert Rev Anti Infect Ther 2014; 12:817-28.
27. Quraishi SA, DePascale G, Needleman JS, et al. Effect of cholecalciferol supplementation on vitamin D status and cathelicidin levels in sepsis: A randomized, placebo-controlled trial. Crit Care Med 2015; 43:1928-37.
28. Gombart AF, Borregaard N, Koeffler HP. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1, 25-dihydroxyvitamin D3. FASEB J 2005; 19:1067-77.
29. McMurdie PJ, Holmes S. phyloseq: An R package for reproducible interactive analysis and graphics of microbiome census data. PLoS One 2013; 8:e61217.
30. Andersson DI, Hughes D, Kubicek-Sutherland JZ. Mechanisms and consequences of bacterial resistance to antimicrobial peptides. Drug Resist Updat 2016; 26:43-57.
31. Kovach MA, Ballinger MN, Newstead MW, et al. Cathelicidin-related antimicrobial peptide is required for effective lung mucosal immunity in gram-negative bacterial pneumonia. J Immunol 2012; 189:304-11.
32. Lambert AA, Kirk GD, Astemborski J, et al. A cross sectional analysis of the role of the antimicrobial peptide cathelicidin in lung function impairment within the ALIVE cohort. PLoS One 2014; 9:e95099.
33. Leow L, Simpson T, Cursons R, Karalus N, Hancox RJ. Vitamin D, innate immunity and outcomes in community acquired pneumonia. Respirology 2011; 16:611-6.
34. Jartti T, Aakula M, Mansbach JM, et al. Hospital length-of-stay is associated with rhinovirus etiology of bronchiolitis. Pediatr Infect Dis J 2014; 33:829-34.
35. Mansbach JM, Hasegawa K, Henke DM, et al. Respiratory syncytial virus and rhinovirus severe bronchiolitis are associated with distinct nasopharyngeal microbiota. J Allergy Clin Immunol 2016; 137:1909-1913.e4.
36. Mansbach JM, Piedra PA, Stevenson MD, et al; MARC-30 Investigators. Prospective multicenter study of children with bronchiolitis requiring mechanical ventilation. Pediatrics 2012; 130:e492-e500.
37. Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006; 311:1770-3.
38. Ralston SL, Lieberthal AS, Meissner HC, et al; American Academy of Pediatrics. Clinical practice guideline: The diagnosis, management, and prevention of bronchiolitis. Pediatrics 2014; 134:e1474-502.
39. Hsieh IN, Hartshorn KL. The role of antimicrobial peptides in influenza virus infection and their potential as antiviral and immunomodulatory therapy. Pharmaceuticals (Basel) 2016; 9:53.